NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 17.11 against a street estimate of 17.30 — a miss of 1.1%.
with an average price target of ₹2,497.73.
CONFIDENT Glenmark delivered 23.1% YoY consolidated revenue growth to INR 40.2B, driven by India outperformance, North America respiratory launches, and emerging markets strength. Oncology momentum (Tevimbra, Brukinsa hit INR 100cr in 12 months) and Ryaltris global expansion (40%+ secondary sales growth, 57 markets) offset European transition headwinds. Q1 FY '27 India and Emerging Markets drove consolidated growth; North America benefited from respiratory launches and deferred income recognition. Europe transitioning from generics to branded specialty; growth expected to accelerate post-launches. Analysts pressed on Europe slowdown, R&D burn scaling, India concentration risk, and U.S. injectables timing. Management reframed Europe as deliberate transition to branded (target 60% revenue, 5-year horizon); defended India portfolio breadth (11 brands in top 300; ranked 2nd derm, 3rd respira…
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 GLENMARK PHARMACEUTICALS LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Dividend declared: INR 2.50 per equity share for Financial Year ended March 3 | 2026-08-13 |
| Q1 FY27 earnings call GLENMARK PHARMACEUTICALS LIMITED – DOCUMENT SUMMARY IMPORTANT NOTE This document is a regulatory filing letter only – it does NOT contain financial r | 2026-08-05 |
| Investor presentation · Q4 FY26 GLENMARK PHARMACEUTICALS LIMITED – INVESTOR DAY 2026 SUMMARY --- HEADLINE NUMBERS • Consolidated revenue: ~US$2 billion (as of FY26) • Global emplo | 2026-06-09 |
| Quarterly results · Q4 FY26 GLENMARK PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY Year Ended 31 March 2026 --- HEADLINE NUMBERS • Standalone Net Sales (FY 2025-26): Rs. 79,342. | 2026-05-29 |
| Investor presentation | 2026-05-29 |
| Q3 FY26 earnings call GLENMARK PHARMACEUTICALS LIMITED - DOCUMENT SUMMARY IMPORTANT NOTE This document is a formal regulatory filing notifying stock exchanges about the av | 2026-02-04 |
| Quarterly results · Q3 FY26 GLENMARK PHARMACEUTICALS LIMITED – Q3 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS STANDALONE BASIS (9 months ended 31 Dec 2025 vs 31 Dec 2024): • Net | 2026-01-30 |
| Investor presentation GLENMARK PHARMACEUTICALS Q3 FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Consolidated Revenue: Rs. 39,006 Million in Q3 FY26, up 15.1% YoY from Rs. 33,8 | 2026-01-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹2.50 / share ex-date Aug 31, 2026 | 2026-08-31 |
| Dividend | ₹2.50 / share ex-date Oct 3, 2025 | 2025-10-03 |
| Dividend | ₹2.50 / share ex-date Sep 15, 2025 | 2025-09-15 |
| Announcement | Date |
|---|---|
| Update on Chhatrapati Sambhajinagar facility operations and development Update on the Company's Chhatrapati Sambhajinagar (Aurangabad) Facility | 2025-12-01 |
| Interim dividend of 2.5 per equity share declared Glenmark Pharmaceuticals' Board of Directors declared an interim dividend of ₹2.50 per equity share on September 26, 2025. What happened: The company decided to distribute cash to its share | 2025-09-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Glenmark Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.